Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Model-informed precision dosing for linezolid in ICU infections
2024-517888-23-00Phase 3Authorised
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of linezolid in bacterial pneumonia and skin and soft tissue infections (SSTIs) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Day 7 trough linezolid concentration within target range. Planned start Jul 2026; status: authorised.
02
Drugs
linezolid
03
Conditions
bacterial pneumoniaskin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2024-517888-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517888-23-00.